Evonik Investors Await Crucial March Update

Evonik's March 4 report, featuring 2026 guidance and a new dividend policy, is crucial for market confidence amid restructuring and sector challenges.

All eyes are on a single date in the calendar for shareholders of Evonik. The German specialty chemicals group is scheduled to release its final 2025 financial results and, more importantly, its official outlook for 2026 on March 4. This forward guidance is anticipated to be pivotal, arriving alongside a recalibrated dividend policy and against a backdrop of ongoing wage disputes within the chemical sector. The central question is whether Evonik’s plans can restore sufficient market confidence.

Recent trading activity has reflected investor unease. The stock closed at €14.73 last Friday, marking a daily decline of 1.60%. However, it has advanced 13.57% over the past 30 days, highlighting the potential for swift sentiment shifts. Notably, the 14-day Relative Strength Index (RSI) sits at 15.8, indicating the equity is in deeply oversold territory.

Strategic Pivot: Dividend Policy and Financial Flexibility

Concurrently with its annual report, Evonik is implementing a significant shift in its shareholder returns framework. Moving forward, the company intends to distribute 40% to 60% of its adjusted net income to investors, a policy first applicable to the 2026 fiscal year. For 2025, the management board will propose an annual dividend of €1.00 per share at the upcoming Annual General Meeting, down from €1.17 previously.

This strategic adjustment underscores a clear priority: bolstering financial flexibility in a challenging operating environment. The company maintains its medium-term target of achieving a Return on Capital Employed (ROCE) of 11%.

March 4: Final Figures and the 2026 Roadmap

The forthcoming report is expected to provide more than finalized accounting. Based on preliminary data, Evonik anticipates an adjusted EBITDA of approximately €1.874 billion, sales of around €14.1 billion, and a free cash flow of roughly €695 million for 2025. The true focal point, however, will be the official 2026 guidance derived from these results.

Management has projected an adjusted EBITDA between €1.7 billion and €2.0 billion for the current year, a range that encapsulates prevailing market uncertainties. Investors will also scrutinize the report for any signals regarding a demand recovery in key customer industries such as automotive and construction.

Restructuring and Sector Headwinds

Internally, Evonik’s transformation program, "Evonik Tailor Made," continues. Upon its expected completion in 2026, the initiative is designed to yield annual savings of about €400 million, with approximately 80% stemming from workforce reductions. The plan involves cutting up to 2,000 positions globally, including some 1,500 in Germany. Organizationally, the company has operated under two segments—"Custom Solutions" and "Advanced Technologies"—since April 1, 2025, each currently generating annual sales in the region of €6 billion.

External pressures add another layer of complexity. Wage negotiations for roughly 585,000 employees in Germany's chemical and pharmaceutical industries remain unresolved after a second round of talks. Discussions are set to resume in Bad Breisig on March 24 and 25. The sector continues to grapple with high energy costs, economic softness, U.S. tariffs, and global overcapacity.

Key Dates for the Diary

Following the annual report on March 4, the company will publish its Q1 2026 quarterly statement on May 8. The virtual Annual General Meeting is scheduled for June 3, where the revised dividend policy and the proposed dividend will be put to a shareholder vote. Additionally, the Chief Financial Officer position remains vacant.